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J. L. Del Pozo,a,b N. Fernández-Ros,a,c E. Sáez,d,e J. I. Herrero,c J. R. Yuste,a,c J. M. Banalesd,e,f
Infectious Diseases Division, Clinica Universidad de Navarra, Pamplona, Spaina; Department of Clinical Microbiology, Clinica Universidad de Navarra, Pamplona, Spainb;
Department of Internal Medicine, Clinica Universidad de Navarra, Pamplona, Spainc; Division of Gene Therapy and Hepatology, School of Medicine and CIMA of the
University of Navarra, Pamplona, Spaind; Department of Liver and Gastrointestinal Diseases, National Institute for the Study of Liver and Gastrointestinal Diseases
(CIBERehd, funded by the Spanish Carlos III Institute), Barcelona, Spaine; Department of Liver and Gastrointestinal Diseases, Biodonostia Research Institute, Donostia
University Hospital, University of Basque Country (UPV), IKERBASQUE (Basque Foundation for Science), San Sebastián, Spainf
Mitochondrial toxicity has been recently suggested to be the underlying mechanism of long-term linezolid-associated toxicity in
patients with 16S rRNA genetic polymorphisms. Here, we report for the first time two cases of lactic acidosis due to long-term
linezolid exposure in liver transplant recipients who presented an A2706Gmitochondrial DNA polymorphism.
Linezolid was the first oxazolidinone to be approved for clinicaluse by the Food and Drug Administration in 2000. This anti-
microbial inhibits bacterial protein synthesis by binding to the 23S
rRNA of the 50S subunit. Linezolid is used to treat a variety of
Gram-positive infections, including those due to methicillin-re-
sistant Staphylococcus aureus and vancomycin-resistant entero-
cocci. In addition, it has been used as a valid alternative in the
management ofNocardia infections,multidrug-resistant tubercu-
losis, and other mycobacterial infections. Linezolid is generally
well tolerated, and most reported adverse effects are mild, tran-
sient, and reversible upon the cessation of therapy. Among the
most common side reactions are gastrointestinal disturbances,
followed by headache and rash. However, long-term use of this
antibiotic can lead to severe toxicity, particularly myelosuppres-
sion, peripheral or optic neuropathy, serotonin syndrome (1), and
lactic acidosis (1–12).
There is evidence that mitochondrial toxicity is the underlying
mechanism of lactic acidosis and peripheral and optic neuropathy
(7, 10). Soriano et al. (10) reported thatmitochondrial respiratory
chain complex IV (synthesized by mitochondrial ribosomes) ac-
tivity was lower in linezolid-treated patients than in nontreated
patients, suggesting a relationship between linezolid-related tox-
icity andmitochondrial protein synthesis inhibition due to poten-
tial structural similarities between bacterial andmitochondrial ri-
bosomes. In addition, De Vriese et al. also reported a decreased
mitochondrial enzymatic activity in a patient treated with lin-
ezolid (6). Moreover, it has been recently described that the pres-
ence of A2706G and G3010A mitochondrial 16S rRNA polymor-
phisms could predispose to the development of linezolid-related
lactic acidosis (4, 11). Here, we have studied the presence of 16S
rRNA polymorphisms in two liver transplant patients who devel-
oped lactic acidosis while receiving linezolid therapy.
Case 1.A 72-year-old diabetic woman was diagnosed with dis-
seminated nocardiosis (i.e., bone and central nervous system). She
had received a liver transplant due to primary biliary cirrhosis 4
years before. Immunosuppression was reduced, and the patient
started antimicrobial treatment. First, the patient received treat-
ment with meropenem that was switched to cotrimoxazole when
Nocardia asteroides was identified. One month later, the patient
was discharged with oral cotrimoxazole (1 double-strength tablet
3 times a day [t.i.d.]). However, 3 months later, even though the
isolate was susceptible to cotrimoxazole, there was no change in
the size of the brain lesions and the leg fracture was not healing.
Antimicrobial therapy was switched to ceftriaxone (2 g twice a day
[b.i.d.]) and linezolid (600 mg b.i.d.). Clinical and radiological
improvements were observed after 4 weeks of treatment. She was
discharged with oral linezolid. Nine weeks later, she was readmit-
ted to our hospital with hypoglycemic coma and lactic acidosis. At
the admission date, arterial blood gas data were as follows: pH
7.25; lactate, 3.20mmol/liter; andHCO3, 15.60mmol/liter. Other
causes of hyperlactatemia were excluded. No evidence of graft
dysfunction was observed. Even though the bicarbonate rate im-
proved with fluid solution, the lactate increased to 4.80 mmol/
liter, and she continuedwith diarrhea and vomiting. Linezolidwas
stopped and doxycycline was started. Thiamine infusion was ad-
ministered. The patient was discharged without gastrointestinal
symptoms and normalization of lactic acid levels. She successfully
completed 1 year of treatmentwith doxycycline (100mg/day). She
has no signs of nocardiosis up to date (i.e., 7 years after nocardiosis
diagnosis).
Case 2. A 43-year-old man was diagnosed with lung tubercu-
losis. Three years before he had received a liver transplant due to
hepatitis C virus-associated cirrhosis. He started treatment with
ethambutol (Myambutol; 400 mg t.i.d.), pyrazinamide (20 mg/kg
of body weight), isoniazid (300 mg), and levofloxacin (500 mg)
per day. He developed severe myalgias, so levofloxacin and pyr-
azinamide were stopped and linezolid (600 mg b.i.d.) was orally
started. The patient was admitted in our hospital 8 weeks after
beginning with linezolid because of nausea, asthenia, and diar-
rhea. The arterial blood gas data were as follows: pH 7.29; lactate,
7.20 mmol/liter; HCO3, 15.60 mmol/liter. He suffered an acute
renal failure with a creatinine clearance of 30 ml/min (creatinine
of 2.5 mg/dl) and pancytopenia. Linezolid was stopped and fluid
resuscitation with bicarbonate was started. Other causes of hyper-
lactatemia were excluded, including sepsis, liver failure, and expo-
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sure to medications generally known to cause it. No evidence of
graft dysfunction was observed. Thiamine infusion was adminis-
tered. The patient improved and lactic acid decreased to normal
values. The antituberculous drugs were changed and ethambutol
was reinitiated, continuing with isoniazid with adequate tolerance
to the treatment. He completed 1 year of treatment and has no
signs of tuberculosis up to date (i.e., 1 year after finishing treat-
ment).
Screening for polymorphisms in mitochondrial 16S rRNAwas
performed as previously reported (7) following both restriction
enzyme digestion and sequencing of PCR fragments amplified
frombloodDNA. A total of 200 ng of genomicDNA isolated from
peripheral blood lymphocytes (Lympholate-H protocol; Cedar-
lane) was used for the PCR. PCR conditions, using the GoTaq
Flexi DNA polymerase (Promega), were as follows: (i) 95°C for 2
min; (ii) 30 cycles at 95°C for 30 s, 57°C for 30 s, and 72°C for 40 s;
and (iii) 1 cycle at 72°C for 7 min. PCR was amplified in a 2720
Thermal Cycler apparatus (Applied Biosystems), and DNA se-
quencing of the PCR products was performed using the BigDye
Terminator 3.1 kit and the ABI PRISM 3120 XL apparatus (Ap-
pliedBiosystems). To identify theA2706Gpolymorphism,we em-
ployed the restriction enzyme NlaIII (New England Biolabs),
which recognizes the 5=-CATG-3= sequence and digests a 237-bp
PCR product (amplified with the following primers: forward, 5=-
ACCGTGCAAAGGTAGCATAA-3=; and reverse, 5=-GCCCCAA
CCGAAATTTTTA-3=) in 2 bands (121 and 116 bp) for the se-
quences containing the A2706G polymorphism but did not cut
thewild-type fragment.On the other hand, to identify theG3010A
polymorphism, we employed the restriction enzyme Bccl (New
England BioLabs), which recognizes the 5=-CCATC-3= sequence
and digests a 1,074-bp PCR product (amplified with the following
primers: forward, 5=-ACTCCTCACACCCAATTGGA-3=; and re-
verse, 5=-GGAGGTTGGCCATGGGTATG-3=) in 3 bands (754,
224, and 96 bp) for wild-type sequences and produces 2 bands
(978 and 96 bp) for the sequences containing the G3010A poly-
morphism. The digestion products were run in a 2.5% agarose gel
and visualized in a GELDOC EQ PC system (Bio-Rad).
The analysis of mitochondrial 16S rRNA revealed that both
patients possessed the A2706G polymorphism. As expected for
this polymorphism, the digestion of the PCR product (237 bp)
with the restriction enzymeNlaIII produced two fragments of 121
and 116 bp (Fig. 1A), being confirmed by sequencing the undi-
gested fragment (Fig. 1B). On the other hand, both patients were
negative for the G3010A polymorphism (data not shown).
To the best of our knowledge, the two cases reported here are
the unique case reports of lactic acidosis due to long-term lin-
ezolid use in liver transplant recipients. Sequencing of mitochon-
drial rRNA genes demonstrated that both patients possessed an
A2706G mitochondrial DNA polymorphism.
Linezolid-related lactic acidosis was first reported by Apodaca
and Rakita (2) in 2003 in a patient who received linezolid for the
treatment of pulmonary nocardiosis. Several cases of linezolid-
induced lactic acidosis have been described in the literature since
then. Nevertheless, not all of the reported cases have occurred
after a prolonged course. Thus, Pea et al. (8) hypothesized that
early-onset hyperlactatemia would happen with drug overexpo-
sure, while late-onset hyperlactatemia would occur after long-
lasting drug exposure. In fact, eight of the 22 reported cases (36%)
in the literature occurred within the first 3 weeks of linezolid ex-
posure (9). It has been proposed that early-onset hyperlactatemia
would happen in relation to a P-glycoprotein inhibition, facilitat-
ing the lactic acidosis due to mitochondrial toxicity (9). The in-
terindividual pharmacokinetic variability of linezolid has been re-
ported to be mild, which is consistent with mainly nonrenal,
nonenzymatic clearance pathways. However, the case of a liver
transplant patient with linezolid plasma levels 4- to 6-fold higher
than expected has been reported (8). It is very difficult even to
hypothesize about which mechanism may have caused this drug
accumulation. Perhaps the critical status of the patient affected
drug clearance. Additionally, a drug-drug interaction might have
occurred.
Trying to identify a gene susceptibility of certain individuals to
linezolid toxic effects, Palenzuela et al. (7) developed a PCR assay
to amplify and sequence mitochondrial 12S and 16S rRNA. They
described two polymorphism in the mitochondrial 16S rRNA
(i.e., A2706G and G3010A) of two patients that could explain a
potential susceptibility to linezolid. In other studies (4, 11), the
presence of the A2706G polymorphism was linked to linezolid-
related lactic acidosis in two patients. Despite these evidences, it is
difficult to conclude about the relationship between the presence
of these polymorphisms and the susceptibility to linezolid-in-
duced lactic acidosis due to themoderate prevalence of these poly-
morphisms in the general population (7). The clinical relevance of
FIG 1 Analysis of mitochondrial 16S rRNA. PCR product (237 bp) digestion
with the restriction enzyme NlaIII produced 2 fragments of 121 and 116 bp
(A), being the sequence confirmed by sequencing the undigested fragment (B).
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reported mitochondrial DNA polymorphisms associated with li-
nezolid-induced lactic acidosis is debatable given the small num-
ber of patients whose mitochondrial DNA has been analyzed to
detect single-nucleotide polymorphisms associated with lactic ac-
idosis. We do not know if the variant was present in the trans-
planted livers, but we believe that it is not justified to determine
liver sequences. As this variant may be common, it is possible that
the variant was present in the transplanted livers.
There is no proven therapy to treat linezolid-induced lactic
acidosis. Removal of the offending agent and care support are the
most importantmeasures. Because themechanism of lactic acido-
sis associated with linezolid might be related to mitochondrial
toxicity, use of respiratory chain cofactors (e.g., thiamine, ribofla-
vin, L-carnitine, or coenzyme Q10) has been attempted in a few
cases as a treatment strategy (4).
In summary, as we report here, the majority of episodes of
linezolid-related hyperlactatemia occur in patients receiving pro-
longed therapy. It could be useful to measure serum lactate levels
in liver transplant patients taking linezolid, especially if they are
taking other drugs potentially able to induce lactic acidosis or to
inhibit the P-glycoprotein or if they have renal insufficiency. In
these patients, it could also be useful to perform a genetic study
looking for the described polymorphisms.
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